Thursday, February 23, 2012

Vivus Soars on an Anti-Obesity Drug’s Likely Approval

XCSFDHG46767FHJHJF

tdp2664 InvestorPlace The recommendation to OK Vivus’s Qnexa has the company’s shares nearly doubling.



No comments:

Post a Comment

LinkWithin

Related Posts Plugin for WordPress, Blogger...